Avalo Therapeutics AVTX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's EBITDA?
- Avalo Therapeutics (AVTX) reported EBITDA of -$20.88M in Q1 2026.
- How has Avalo Therapeutics's EBITDA changed year-over-year?
- Avalo Therapeutics's EBITDA decreased by 43.7% year-over-year, from -$14.53M to -$20.88M.
- What is the long-term trend for Avalo Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Avalo Therapeutics's EBITDA has grown at a -2.5% compound annual growth rate (CAGR), from -$80.48M to -$72.58M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.